JP2018520679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520679A5 JP2018520679A5 JP2017568207A JP2017568207A JP2018520679A5 JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5 JP 2017568207 A JP2017568207 A JP 2017568207A JP 2017568207 A JP2017568207 A JP 2017568207A JP 2018520679 A5 JP2018520679 A5 JP 2018520679A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- recombinant cell
- intracellular signaling
- protein
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 108091008042 inhibitory receptors Proteins 0.000 claims description 18
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 claims description 17
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 claims description 17
- 108091005703 transmembrane proteins Proteins 0.000 claims description 13
- 102000035160 transmembrane proteins Human genes 0.000 claims description 13
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000005965 immune activity Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 230000001461 cytolytic effect Effects 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 206010010144 Completed suicide Diseases 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000001146 hypoxic effect Effects 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186108P | 2015-06-29 | 2015-06-29 | |
| US62/186,108 | 2015-06-29 | ||
| PCT/US2016/040010 WO2017004150A1 (en) | 2015-06-29 | 2016-06-29 | Immune checkpoint chimeric antigen receptors therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520679A JP2018520679A (ja) | 2018-08-02 |
| JP2018520679A5 true JP2018520679A5 (enExample) | 2019-08-08 |
Family
ID=57609024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568207A Pending JP2018520679A (ja) | 2015-06-29 | 2016-06-29 | 免疫チェックポイントキメラ抗原受容体療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180185434A1 (enExample) |
| EP (1) | EP3313892A4 (enExample) |
| JP (1) | JP2018520679A (enExample) |
| KR (1) | KR20180038447A (enExample) |
| CN (1) | CN108137707A (enExample) |
| AU (1) | AU2016285859A1 (enExample) |
| CA (1) | CA2991040A1 (enExample) |
| HK (2) | HK1254820A1 (enExample) |
| IL (1) | IL256643A (enExample) |
| MA (1) | MA42272A (enExample) |
| MX (1) | MX2018000278A (enExample) |
| WO (1) | WO2017004150A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| ES2914176T3 (es) | 2013-09-17 | 2022-06-07 | Obi Pharma Inc | Composiciones de una vacuna glucídica para inducir respuestas inmunitarias y usos de las mismas en el tratamiento de cáncer |
| US10428305B2 (en) | 2014-05-15 | 2019-10-01 | National University Of Singapore | Modified natural killer cells that express IL15 and uses thereof |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| MA42902A (fr) | 2015-07-08 | 2018-05-16 | Univ Johns Hopkins | Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car) |
| US10590169B2 (en) * | 2015-12-09 | 2020-03-17 | Virogin Biotech Canada Ltd | Compositions and methods for inhibiting CD279 interactions |
| EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| JP7544465B2 (ja) | 2016-04-22 | 2024-09-03 | オービーアイ ファーマ，インコーポレイテッド | グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法 |
| KR20190067765A (ko) | 2016-07-27 | 2019-06-17 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| TWI786054B (zh) | 2016-07-29 | 2022-12-11 | 台灣浩鼎生技股份有限公司 | 人類抗體、醫藥組合物、及其方法 |
| KR20190077103A (ko) | 2016-11-21 | 2019-07-02 | 오비아이 파머 인코퍼레이티드 | 접합된 생물학적 분자, 제약 조성물 및 방법 |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| CN110267666A (zh) * | 2016-12-22 | 2019-09-20 | 温德弥尔治疗公司 | 用于调节免疫系统的组合物和方法 |
| AU2018246235B2 (en) | 2017-03-27 | 2023-12-21 | National University Of Singapore | Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| US10934336B2 (en) * | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| US12258381B2 (en) | 2018-02-09 | 2025-03-25 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019193476A1 (en) | 2018-04-02 | 2019-10-10 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| AU2019387242A1 (en) * | 2018-11-30 | 2021-06-03 | Windmil Therapeutics, Inc. | Marrow infiltrating lymphocytes (MILs) expressing chimeric antigen receptors (CAR), method of manufacturing same, and method of using in therapy |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| WO2022098985A1 (en) * | 2020-11-05 | 2022-05-12 | Windmil Therapeutics, Inc. | Glioblastoma specific marrow infiltrating lymphocytes and uses thereof |
| WO2022109601A1 (en) * | 2020-11-19 | 2022-05-27 | Obi Pharma, Inc. | Active cancer immunotherapy by immune modulation via globo series antigens |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141520A1 (es) * | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| WO2014184744A1 (en) | 2013-05-13 | 2014-11-20 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| WO2016019300A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| CN107109364A (zh) * | 2014-09-04 | 2017-08-29 | 约翰霍普金斯大学 | 缺氧与常氧交替条件下的骨髓浸润淋巴细胞的激活 |
| EP3310805B1 (en) * | 2015-06-19 | 2021-02-17 | Kobold, Sebastian | Pd-1-cd28 fusion proteins and their use in medicine |
-
2016
- 2016-06-29 HK HK18113910.0A patent/HK1254820A1/zh unknown
- 2016-06-29 MA MA042272A patent/MA42272A/fr unknown
- 2016-06-29 KR KR1020187002679A patent/KR20180038447A/ko not_active Withdrawn
- 2016-06-29 HK HK18114773.4A patent/HK1255637A1/zh unknown
- 2016-06-29 AU AU2016285859A patent/AU2016285859A1/en not_active Abandoned
- 2016-06-29 WO PCT/US2016/040010 patent/WO2017004150A1/en not_active Ceased
- 2016-06-29 US US15/740,981 patent/US20180185434A1/en not_active Abandoned
- 2016-06-29 CN CN201680048831.3A patent/CN108137707A/zh active Pending
- 2016-06-29 JP JP2017568207A patent/JP2018520679A/ja active Pending
- 2016-06-29 MX MX2018000278A patent/MX2018000278A/es unknown
- 2016-06-29 CA CA2991040A patent/CA2991040A1/en not_active Abandoned
- 2016-06-29 EP EP16818647.6A patent/EP3313892A4/en not_active Withdrawn
-
2017
- 2017-12-28 IL IL256643A patent/IL256643A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520679A5 (enExample) | ||
| van Montfoort et al. | NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines | |
| Mitra et al. | Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps | |
| Gargett et al. | GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade | |
| JP6917896B2 (ja) | 免疫調節性融合タンパク質およびその使用 | |
| Prosser et al. | Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1: CD28 chimeric receptor | |
| Geller et al. | Use of allogeneic NK cells for cancer immunotherapy | |
| JP2017522862A5 (enExample) | ||
| IL292650B2 (en) | COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2 | |
| JP7146397B2 (ja) | 改変γδＴ細胞 | |
| Sehgal et al. | Programmed death-1 checkpoint blockade in acute myeloid leukemia | |
| JP2020512284A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| JP2017515464A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| JP2017535292A5 (enExample) | ||
| JP2018029594A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2018522592A5 (enExample) | ||
| RS63574B1 (sr) | Metode za povećanje efikasnosti imuno ćelija | |
| FI3909972T3 (fi) | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä | |
| JP2016534717A5 (enExample) | ||
| JP2019518460A5 (enExample) | ||
| Tang et al. | CD137 co-stimulation improves the antitumor effect of LMP1-specific chimeric antigen receptor T cells in vitro and in vivo |